ISPECIMEN INC

ISPCNASDAQ

🏆 #4052 by market capEarnings Nov 5US Equity

$2.28▲ $0.04 (+1.79%)

🌙 After hours$2.26▼ 1.03%Regular close · extended-hours price shown

1h—

24h▲ 1.8%

7d—

14d—

30d—

1y—

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

-87.3%

Declining

📊Gross Margin

-28.8%

Thin

💵FCF Margin

—

⚖️P/S Ratio

3.3x

Fair

Otter Score

Fair

No chart data available for ISPC.

Trading Snapshot

Day Range: $2.25 – $2.31
52-Week Range: $1.77 – $127.20
Volume: $2.93B
Avg Volume: $2.43B
Shares Outstanding: 1.4M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $156,009
P/E Ratio: —
P/S Ratio: 3.3x
EPS (TTM): $-68.43
Dividend Yield: —

Why Investors Own ISPC

✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
✓Healthy economics — 33% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +62.5% YoY

Gross Margin (TTM)

32.6%▲ +3.7% YoY

Operating Income (TTM)

$551,693▲ +62.5% YoY

Free Cash Flow (TTM)

$175,539▲ +62.5% YoY

About ISPECIMEN INC

iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.

🦦